Table 4.
EGFR and HER2 expression in primary tumor and in CTCs
| Early disease | Metastatic disease | |||||||
| Primary tumor | CTCs | Primary tumor | CTCs | |||||
| Patient number | HER2 | EGFR | HER2 | EGFR | HER2 | EGFR | HER2 | EGFR |
| 1 | - | + | + | + | - | - | + | - |
| 2 | +a | NA | + | - | + | - | + | - |
| 3 | - | - | - | + | + | NA | + | + |
| 4 | - | - | + | - | - | - | - | - |
| 5 | - | - | + | - | - | - | + | - |
| 6 | - | NA | + | + | - | NA | - | - |
| 7 | - | + | - | + | + | - | + | - |
| 8 | - | - | - | - | - | - | + | - |
| 9 | + | - | - | - | - | NA | - | - |
| 10 | + | - | + | + | + | - | + | + |
| 11 | - | + | - | - | + | NA | - | + |
| 12 | - | - | + | - | - | + | - | - |
| 13 | - | - | + | - | - | NA | - | + |
| 14 | - | - | - | - | - | - | + | + |
| 15 | - | NA | - | - | - | NA | + | + |
| 16 | NA | NA | - | + | - | - | + | + |
aScore +3 or fluorescence in situ hybridization positive. CTC, circulating tumor cell; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor.